The prognostic value of amyloid imaging
- 11 April 2012
- journal article
- review article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 39 (7) , 1207-1219
Abstract
Mild cognitive impairment is characterized by a decline in cognitive performance without interference with activities of daily living. The amnestic subtype of mild cognitive impairment progresses to Alzheimer’s disease at a rate of 10–15 % per year and in the majority the neuropathology is intermediate between the neuropathological changes of typical ageing and Alzheimer’s disease. Amyloid deposition occurs over a decade before the development of noticeable cognitive symptoms in a continuous process that starts in healthy elderly individuals. Newly developed PET amyloid imaging agents provide noninvasive biomarkers for the early in vivo detection of Alzheimer’s pathology in healthy elderly individuals and those with mild cognitive impairment. Exclusion of amyloid pathology should allow a more accurate prognosis to be given and ensure appropriate recruitment into clinical trials testing the efficacy of new putative antiamyloid agents at an earlier disease stage. The development of 18F-labelled amyloid imaging agents has increased the availability of this new technology for clinical and research use since they can be used in PET centres where a cyclotron and radiochemistry are not available. This review discusses the role of PET imaging for assessing the amyloid load in cognitively normal elderly subjects and subjects with mild cognitive impairment at risk of conversion to Alzheimer’s disease.Keywords
This publication has 91 references indexed in Scilit:
- Longitudinal assessment of Aβ and cognition in aging and Alzheimer diseaseAnnals of Neurology, 2011
- Cognition, reserve, and amyloid deposition in normal agingAnnals of Neurology, 2010
- APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal agingAnnals of Neurology, 2010
- Cognitive Decline and Brain Volume Loss as Signatures of Cerebral Amyloid-β Peptide Deposition Identified With Pittsburgh Compound BArchives of Neurology, 2009
- Detection of amyloid in Alzheimer’s disease with positron emission tomography using [11C]AZD2184European Journal of Nuclear Medicine and Molecular Imaging, 2009
- Amyloid imaging in mild cognitive impairment subtypesAnnals of Neurology, 2009
- Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the ElderlyArchives of Neurology, 2008
- ApoE Promotes the Proteolytic Degradation of AβNeuron, 2008
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991